Crispr Therapeutics AG Dividends
The next dividend date for Crispr Therapeutics AG has not yet been scheduled.
What is a Dividend Date
When we talk about a dividend date, we’re referring specifically to the ex-dividend date.
This is the date on which all stockholders will earn a dividend. Technically, a person needs to be the owner of a share of stock as of the night before the ex-dividend date in order to earn the dividend.
The ex-dividend date is different than the date when the dividend is issued. Although you earn a dividend on the ex-dividend date, that dividend is typically not disbursed to your account until several weeks later.
Most brokerages will automatically credit the dividend to your account once it’s issued.
Historical Dividends for Crispr Therapeutics AG (CRSP)
More About Crispr Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Owning Crispr Therapeutics AG Stock on the Dividend Date
If you own Crispr Therapeutics AG stock on the ex-dividend date, then you earn the associated dividend.
Theoretically, the price of Crispr Therapeutics AG stock should go down by the amount of the dividend (in addition to any other pressures that market forces have on the price of Crispr Therapeutics AG stock).
Therefore, it is typically not expected that there is any incremental profit to be gained from buying Crispr Therapeutics AG stock right before the ex-dividend date and then selling it immediately after. It’s not like you get the Crispr Therapeutics AG dividend payout for free just by doing that since there is typically an equivalent commensurate drop in the stock price.
Owning Crispr Therapeutics AG Options on the Dividend Date
Unlike the stock price, which will normally have an abrupt decrease by the amount of the dividend on the ex-dividend date, option prices typically do not reflect the same phenomenon.
The reason is that in the time leading up to the ex-dividend date, that projected drop in Crispr Therapeutics AG stock price from the dividend is already baked into Crispr Therapeutics AG option prices.
That means the prices of call options that overlap the Crispr Therapeutics AG ex-dividend date typically go down in the period leading up to the ex-dividend date.
The prices of put options that overlap the Crispr Therapeutics AG ex-dividend date typically go up in the period leading up to the ex-dividend date.
Owners of Crispr Therapeutics AG call options do not receive the dividend, even if they own the options on the ex-dividend date. Owners of Crispr Therapeutics AG put options are not responsible to pay the dividend, even if they own the options on the ex-dividend date.
Learning More Crispr Therapeutics AG Dividends
You can contact us any time if you would like to ask questions about Crispr Therapeutics AG dividends or anything else related to the stock market.